Product Description
ICP-B05 selectively depletes Tregs in the tumor microenvironment, which is more specific than other immunotherapies. CM369 binds to CCR8 on Tregs and eradicates immunosuppressive Tregs through ADCC to augment the anti-tumor immunity in TME while preserving peripheral homeostasis. CM369 has the potential to deliver optimal tumor targeted Treg depletion and be more specific in anti-tumor activity than other immunotherapies. It is an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody. (Sourced from: https://www.innocarepharma.com/en/media/press-release/20230224/)
Mechanisms of Action: CCR8 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innocare Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CM369-001 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified |
2025-10-30 |
50% |
2024-12-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| CTR20223403 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/20/2024 |
News Article |
InnoCare Releases 2024 Interim Results and Business Highlights |
|
03/28/2024 |
News Article |
InnoCare Releases 2023 Results and Business Highlights |
|
08/29/2023 |
News Article |
InnoCare Releases 2023 Interim Results and Business Highlights |
|
03/27/2023 |
News Article |
InnoCare Releases 2022 Annual Results and Business Highlights |